Abstract

Core B, will be responsible for the processing and interpretation of all cervical cytologic smears and biopsies obtained from women enrolled n Projects 1 and 2. These specimens will be tested (Core A) for the presence of HPV DNA by polymerase chain reaction and by Southern transfer hybridization. Core B will be responsible for testing all specimens (during study years 1 and 2) for the presence of HPV DNA, using Virapap reagents. This strategy has been chosen because PCR is an evolving technology with the sensitivity, specificity, and reproducibility still to be established before it can be used as the gold standard for the detection of HPV DNA. In addition, Southern transfer hybridization does not readily allow for the efficient screening of large numbers of specimens. Use of the Virapap reagents provides for rapid,, reliable screening; positive results will be typed by Southern transfer hybridization (Core A); and Virapap results, when used in conjunction with PCR, will provide valuable insights into the epidemiology of HPV infections.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI029363-05
Application #
3747079
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1994
Total Cost
Indirect Cost

  Institution

Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109

  Publications

Watts, D H; Koutsky, L A; Holmes, K K et al. (1998) Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am J Obstet Gynecol 178:365-73
Carter, J J; Koutsky, L A; Wipf, G C et al. (1996) The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174:927-36
Hagensee, M E; Carter, J J; Wipf, G C et al. (1995) Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies. Virology 206:174-82
Ostrow, R S; Coughlin, S M; McGlennen, R C et al. (1995) Serological and molecular evidence of rhesus papillomavirus type 1 infections in tissues from geographically distinct institutions. J Gen Virol 76 ( Pt 2):293-9
Baken, L A; Koutsky, L A; Kuypers, J et al. (1995) Genital human papillomavirus infection among male and female sex partners: prevalence and type-specific concordance. J Infect Dis 171:429-32
Xi, L F; Demers, G W; Koutsky, L A et al. (1995) Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J Infect Dis 172:747-55
Carter, J J; Hagensee, M B; Lee, S K et al. (1994) Use of HPV 1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts. Virology 199:284-91
McDougall, J K (1994) Immortalization and transformation of human cells by human papillomavirus. Curr Top Microbiol Immunol 186:101-19
Xi, L F; Demers, W; Kiviat, N B et al. (1993) Sequence variation in the noncoding region of human papillomavirus type 16 detected by single-strand conformation polymorphism analysis. J Infect Dis 168:610-7
Merrick, D T; Gown, A M; Halbert, C L et al. (1993) Human papillomavirus-immortalized keratinocytes are resistant to the effects of retinoic acid on terminal differentiation. Cell Growth Differ 4:831-40

Showing the most recent 10 out of 17 publications